LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

ACADIA Pharmaceuticals Inc

Closed

SectorHealthcare

24.74 5.01

Overview

Share price change

24h

Current

Min

23.52

Max

24.85

Key metrics

By Trading Economics

Income

7.7M

27M

Sales

20M

265M

P/E

Sector Avg

19.09

35.664

Profit margin

10.079

Employees

653

EBITDA

21M

40M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+27.06% upside

Market Stats

By TradingEconomics

Market Cap

260M

4.3B

Previous open

19.73

Previous close

24.74

News Sentiment

By Acuity

13%

87%

14 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

15 Sept 2025, 22:39 UTC

Acquisitions, Mergers, Takeovers

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 Sept 2025, 16:43 UTC

Major Market Movers

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 Sept 2025, 16:42 UTC

Major Market Movers

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 Sept 2025, 16:35 UTC

Major Market Movers

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 Sept 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 Sept 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 Sept 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 Sept 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 Sept 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

CSL Expects Commercial Launch in 2029

15 Sept 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 Sept 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 Sept 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 Sept 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 Sept 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 Sept 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 Sept 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 Sept 2025, 21:14 UTC

Acquisitions, Mergers, Takeovers

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 Sept 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 Sept 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 Sept 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 Sept 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 Sept 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15 Sept 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 Sept 2025, 17:50 UTC

Acquisitions, Mergers, Takeovers

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 Sept 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 Sept 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 Sept 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 Sept 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15 Sept 2025, 16:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

27.06% upside

12 Months Forecast

Average 30 USD  27.06%

High 40 USD

Low 17 USD

Based on 16 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

16 ratings

10

Buy

5

Hold

1

Sell

Technical Score

By Trading Central

14.845 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

14 / 371 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
help-icon Live chat